Animal models for probiotics intervention on metabolic syndrome  

作　　者：Penggang He Qianyu Qu Zhujun Zhong Peibin Zeng 

机构地区：[1]West China School of Public Health and West China Fourth Hospital,Sichuan University,Chengdu,Sichuan 610041,China

出　　处：《Chinese Medical Journal》2023年第22期2771-2772,共2页中华医学杂志（英文版）

基　　金：supported by the Science and Technology Poverty Alleviation Project,Department of Science and Technology,Sichuan Province(No.2021ZHFP0162)

摘　　要：To the Editor:Metabolic syndrome(MetS),defined as a pathologic condition characterized by obesity,hypertension,hyperlipidemia,and insulin resistance,could increase the risk of type 2 diabetes mellitus(T2DM)and cardiovascular disease.[1]The pathogenesis of MetS is complex,involving various factors such as genetics,gut microbes,diet,and lifestyle.It has been recognized as one of the major threats to human health.Animal studies have described that probiotics,including Lactobacillus and Bifidobacterium,may play significant roles in modulating the host’s metabolic abnormalities by shaping gut microbes and increasing the production of signal molecules,such as short-chain fatty acids(SCFAs).

关 键 词：Animal CARDIOVASCULAR OBESITY 

分 类 号：R589[医药卫生—内分泌] R-332[医药卫生—内科学]